Institut de Cancérologie Lucien Neuwirth Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Saint-Priest-en-Jarez France (2005)

Organization Overview

First Clinical Trial
2017
NCT03317613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Institut de Cancérologie Lucien Neuwirth

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Feeding and Eating Disorders (Phase 2)

Neoplasms (Phase 2)

Neuralgia (Phase 2)

Radiodermatitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 8